Oncotarget

Research Papers:

Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers

Ami N. Shah _, Ashwin Sunderraj, Brian Finkelman, Sharlene H. See, Andrew A. Davis, Lorenzo Gerratana, Firas Wehbe, Neelima Katam, Deva Mahalingam, William J. Gradishar, Amir Behdad, Luis Blanco and Massimo Cristofanilli

PDF  |  Full Text  |  How to cite  |  Order a Reprint

Oncotarget. 2022; 13:273-280. https://doi.org/10.18632/oncotarget.28188

Metrics: PDF 557 views  |   Full Text 1143 views  |   ?  


Abstract

Ami N. Shah1, Ashwin Sunderraj1, Brian Finkelman2, Sharlene H. See1, Andrew A. Davis3, Lorenzo Gerratana4, Firas Wehbe1, Neelima Katam1, Deva Mahalingam1, William J. Gradishar1, Amir Behdad1, Luis Blanco1 and Massimo Cristofanilli1

1 Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA

2 Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA

3 Siteman Cancer Center of Washington University, St. Louis, MO, USA

4 Department of Medical Oncology, Centro di Riferimento Oncologico (CRO), IRCCS, Aviano, Italy

Correspondence to:

Ami N. Shah, email: amishah@northwestern.edu

Keywords: ERBB2; HER2; next-generation sequencing; copy number gain; circulating tumor DNA

Received: November 30, 2021     Accepted: January 10, 2022     Published: February 02, 2022

Copyright: © 2022 Shah et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Background: The correlation of ERBB2 copy number gain (CNG) from tissue or circulating tumor DNA (ctDNA) by next-generation sequencing (NGS) with standard HER2 tissue evaluation is not well understood.

Materials and Methods: We retrospectively identified patients with ERBB2 CNG on commercial NGS. We described their clinical-pathologic features and calculated the positive predictive value (PPV) of ERBB2 CNG by NGS for HER2-positivity by IHC and FISH testing.

Results: 176 patients had NGS revealing an ERBB2 CNG (112 by tumor tissue and 91 by ctDNA). The cancer subtypes with the most cases with ERBB2 CNG by NGS were breast (n = 67), non-small cell lung (n = 25), colorectal (n = 18), gastroesophageal (n = 17), pancreatic (n = 11), and uterine (n = 11). The PPV of ERBB2 CNG in determining HER2 positivity by standard IHC/FISH definitions was 88% for tissue NGS (n = 57) and 80% for ctDNA (n = 47). The PPV among breast cancer patients for tissue NGS was 97% (n = 35) and ctDNA was 93% (n = 39). However, for non-breast cancer cases, the PPV of ERBB2 amplification by tissue NGS dropped to 76% (n = 22) and by ctDNA to 44% (n = 7).

Conclusions: ERBB2 CNG by NGS is detected in numerous malignancies for which HER2 testing is not standard. Detection of ERBB2 CNG by tissue NGS and ctDNA has a high PPV for true HER2-positivity by standard IHC and/or FISH testing in breast cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 28188